Related Experiment Videos
Antithrombotic therapy in atrial fibrillation.
1Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA. dsinger@partners.org
Clinics in Geriatric Medicine
|March 29, 2001
Summary
Anticoagulation effectively prevents stroke in atrial fibrillation (AF) patients, though it carries a small bleeding risk. Aspirin is an alternative for lower-risk individuals, but further research is needed for the oldest AF patients.
Area of Science:
- Cardiology
- Neurology
- Geriatrics
Background:
- Atrial fibrillation (AF) affects 10% of individuals over 80.
- AF significantly increases ischemic stroke risk fivefold.
- Anticoagulation is a proven stroke-prevention strategy for AF.
Purpose of the Study:
- To review the efficacy and safety of anticoagulation and aspirin for stroke prevention in AF.
- To identify risk factors for stroke in AF patients.
- To highlight areas for future research in AF stroke prevention.
Main Methods:
- Review of randomized controlled trials on anticoagulation and aspirin in AF.
- Analysis of stroke and hemorrhage risks associated with different treatments.
- Identification of patient subgroups based on stroke risk factors.
Main Results:
- Anticoagulation significantly reduces stroke risk in AF patients with a <0.5% annual intracranial hemorrhage risk.
- Aspirin shows a small stroke-preventive effect.
- Key stroke risk factors include prior stroke, hypertension, diabetes, and older age.
Conclusions:
- Anticoagulation is recommended for high-risk AF patients.
- Aspirin is suitable for lower-risk individuals.
- Further research is crucial for optimizing stroke prevention in the oldest AF patients and improving risk stratification.